Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for prevention of cirrhosis decompensation or liver-related death in asymptomatic CSPH
2024-511663-28-00Phase 4Authorised
- Sponsor
- CHRU Tours
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of carvedilol and Placebo-COD Research Private Ltd in Cirrhosis and Portal Hypertension (PH) (2 arms), sponsored by CHRU Tours. Primary endpoint: Occurrence of decompensation of cirrhosis or liver-related death. Planned start Feb 2025; status: authorised.
02
Drugs
carvedilolPlacebo-COD Research Private Ltd
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on 2024-511663-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511663-28-00.